ArticleInternational journal of hematology2026
"A tale of the uncommon: a case series on extramedullary plasmacytoma of the head and neck region: A single institutional study".
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtramedullary plasmacytoma is a rare tumor, that primarily occurs in the head and neck region. We report a case series on head and neck extramedullary plasmacytoma treated with radiation therapy to provide insights regarding clinical outcomes. MATERIALS AND
methodsThis was a retrospective study on radiation therapy outcomes in patients with head and neck extramedullary plasmacytoma treated between January 2010 and December 2024. The treatment course was evaluated, in terms of local tumor control rates and treatment-related toxicities.
resultsA total of 200 plasmacytoma patients were screened, and 6 patients with extramedullary disease were included in the study. The most common site of occurrence was the larynx. Radiation therapy was administered at a dose of 45-50 Gy in 20-25 fractions. At a mean follow-up of 8 years, overall survival and disease-free survival were 8 and 7 years, respectively. A local control rate of 83% was achieved through radiation therapy alone. One of six patients progressed to multiple myeloma at 3 months; and all patients were alive as of the last follow-up.
conclusionIn head and neck extramedullary plasmacytoma, radiation offers excellent local control with acceptable toxicities while also preserving organ function.
Indexed as
Identifiers
41166053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.